Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

1999-05-31

Study Completion Date

2001-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Coronary artery disease (CAD) can cause poor blood flow and supply to the heart muscle. It can result in irreversible damage to the heart muscle and poor function. Before treating patients with heart disease it is important to know how well the heart is functioning. Echocardiography is a diagnostic test that can measure heart function. If part of the heart muscle is not working properly due to previous damage, echocardiography can provide information about how much improvement can be expected after treatment (surgery or angioplasty).

The purpose of this study is to compare the accuracy of myocardial contrast echocardiography (MCE) to dobutamine echocardiography to detect the potential for damaged heart muscle to be treated and function in patients with heart disease.

Myocardial contrast echocardiography (MCE) does not use radioactivity. It uses sound waves like standard echocardiography. However, with MCE patients receive an injection of a "contrast agent" directly into the blood stream through a vein. The contrast agent, called Optison, is made of tiny microbubbles smaller than red blood cells. The echocardiogram can detect these microbubbles in the small blood vessels of the heart muscle and allow researchers to find areas of the heart receiving less blood flow than others.

Echocardiography with Dobutamine does not use radioactivity. It uses sound waves, like standard echocardiography. During this echocardiogram patients receive doses of a medication called dobutamine that stimulates the heart to beat stronger and faster. Heart muscle that does not beat stronger after dobutamine is probably dead, usually as a result of a previous heart attack.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Echocardiographic Techniques in Diagnosis of Coronary Artery Disease

NCT00001889

Coronary Disease

COMPLETED PHASE2

Investigation of Heart Function in Patients With Heart Valve Defects

NCT00001314

Aortic Valve Insufficiency Mitral Valve Insufficiency

COMPLETED

Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization

NCT00074724

Cardiovascular Diseases Coronary Disease Heart Failure +2 more

COMPLETED NA

Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging

NCT00861848

Kawasaki Disease Heart Disease

COMPLETED

Electromechanical Mapping to Evaluate Heart Muscle

NCT00001895

Myocardial Ischemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dobutamine echocardiography has become a valuable technique for the evaluation of myocardial viability in patients with coronary artery disease (CAD) and dysfunctional myocardium because it can accurately predict which myocardial segments will show contractile recovery after successful revascularization. Myocardial contrast echocardiography (MCE) offers the potential to evaluate tissue perfusion at the level where oxygen transfer to the myocytes occurs. MCE, therefore, can provide information regarding the functional status of the myocardial microvasculature which has a close relationship with myocellular integrity. The purpose of this study is to evaluate the accuracy of MCE compared to dobutamine echocardiography to detect myocardial viability in patients with CAD and resting wall motion abnormalities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Disease Heart Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Myocardial contrast echocardiography

Intervention Type PROCEDURE

Dobutamine echocardiography

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients undergoing evaluation for CAD who show at least two myocardial segments with wall motion abnormalities on a baseline echocardiogram will be offered to participate in this study.

Patients will be adults older than 21 years of age.

No pre-menopausal patients who are lactating, are pregnant or potentially pregnant as judged by history, physical examination, ultrasound or urine pregnancy test.

No one with unstable angina.

No subjects with recent myocardial infarction (less than 1 month).

No one with frequent ectopy which precludes adequate imaging acquisition.

No subjects with significant hypertension (systolic blood pressure greater than 170 mm Hg).

No hypotension with basal sitting systolic arterial pressure less than 100 mm HG confirmed 30 minutes later.

No subjects with sinus tachycardia greater than or equal to 100 beats/minute.

No atrial fibrillation.

No inadequate two-dimensional echocardiographic windows.

Eligible Sex

ALL

Accepts Healthy Volunteers

No